Gastric cancer is one of the most common cancers in the world; almost two-thirds of gastric cancer cases and deaths occur in less developed regions. The molecular and cellular events during development of gastric cancer remain unclear. Herein, we examined the expression of ER-·36, an ER-· variant, in established gastric cancer cell lines and specimens from 22 gastric cancer patients. RT-PCR, Western blot and immunohistochemistry methods were used to assess expression levels of ER-·36. ER-·36 localization in gastric cancer cells was determined with an immunofluorenscence assay. Both mRNA and protein of ER-·36 were detected in all established gastric cancer cell lines examined. Higher levels of ER-·36 mRNA were expressed in 17 of 22 (77.27%) tumor specimens examined compared to the paired normal tissues (p<0.05). ER-·36 protein was expressed mainly on the plasma membrane and in the cytoplasm of the established gastric cancer cells. ER-·36 expression is highly correlated with lymph node metastasis in human gastric cancer (P<0.05). The estrogen receptor variant ER-·36 is highly expressed in human gastric cancer. ER-·36 expression may be used as a predictive marker for lymph node metastasis of gastric cancer.
Introduction
Estrogen signaling is pivotal in the establishment and maintenance of reproductive function in men and women. It is also involved in normal development and physiology of bone, cardiovascular and neuronal systems. It is believed that dysregulated estrogen signaling is involved in the initiation and development of neoplasia in at least breast and endometrial cancers (1) . However, the involvement of estrogen signaling in other types of human cancer has not been well established.
The diverse physiological functions of estrogens are mediated by specific nuclear receptors designated as estrogen receptors (ERs). In 1986, the cloning of the estrogen receptor (ER) was first reported (2, 3) . Until 1996, it was assumed that there was only one ER responsible for all of the physiological and pharmacological effects of natural and synthetic estrogens and antiestrogens. However, in 1996, a second ER was cloned (4) . Currently, the first ER discovered is referred to as ER-·, while the second is called ER-ß.
ER-· and ER-ß share a common structural architecture (5, 6) . Both are composed of three independent but interacting functional domains: the N-terminal A/B domain, the C or DNA-binding domain, and the D/E/F or ligand-binding domain. The N-terminal domain of ER-· encodes a ligandindependent activation function (AF-1), a region involved in interaction with co-activators, and transcriptional activation of target-genes. The DNA-binding domain or C domain contains a two zinc-finger structure, which plays an important role in receptor dimerization and binding to specific DNA sequences. The C-terminal E/F domain is a ligand-binding domain that mediates ligand binding, receptor dimerization, nuclear translocation, and a ligand-dependent transactivation function (AF-2).
It has been well documented that the ERs are ligandactivated transcription factors that stimulate target gene transcription (1) . Stimulation of target gene expression by ERs in response to estrogens is prevailingly thought to be responsible for cell proliferation. Despite the clarity with which ERs have been shown to act as transcription factors, it became apparent that not all of the physiological effects mediated by estrogens are accomplished through a direct A variant of estrogen receptor-·, ER-·36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis effect on gene transcription. Another signaling pathway (also known as a 'non-classic', 'non-genomic' or 'membrane signaling' pathway) exists that involves cytoplasmic proteins, growth factors and other membrane-initiated signaling pathways (7) . Previously, we identified and cloned a novel variant of ER-·, ER-·36, with a molecular weight of 36 kDa (8, 9) . ER-·36 lacks both transactivation domains AF-1 and AF-2 of the 66-kDa full-length ER-· (ER-·66) (8, 9) . The transcripts of ER-·36 are initiated from a previously unidentified promoter located in the first intron of the ER-·66 gene (8) . Further research found that ER-·36 is subjected to a transcriptional regulation totally different from the ER-·66 (10) .
Estrogens have been proposed to provide protection against gastric cancer of women before menopause (11) ; the incidence of gastric cancer is higher in men than in women before menopause (12) . The incidence of gastric cancer in women after menopause reaches a level similar to men (13). These findings suggested an involvement of estrogen signaling in protection against human gastric cancer. Tokunaga et al (14) first reported ER-·66 expression in human gastric cancer. Since then, a number of laboratories have reported expression of ER-· in gastric cancer and correlated ER status to tumor grade (15, 16) . In addition, the effects of estrogens on the growth of human gastric cancer xenografts in nude mice were studied (17) . It was found that ER-·66 was expressed mainly in the cytoplasm of gastric carcinoma cells while it is predominantly expressed in the cell nuclear of breast cancer cells (18) .
In the present study, we examined the expression and localization of ER-·36 in established gastric cancer cells and specimens from gastric cancer patients. We also examined correlations between ER-·36 expression and lymph node metastasis of human gastric adenocarcinoma.
Materials and methods
Cell culture. Human gastric adenocarcinoma cell lines BGC-823 and SGC7901 were obtained from Cell Center of Basic Medicine, Chinese Academy of Medical Sciences (Beijing, China). Human gastric cancer cell line AGS and breast cancer cell line MCF-7 were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Human gastric cancer cell line MKN-45 was kindly provided by the laboratory of Molecular and Immunopharmacology of Tongji Medical College. All cells were maintained in RPMI-1640 medium plus 10% FCS at 37˚C in a 5% CO 2 atmosphere.
Gastric tumor samples. Tumor tissues, corresponding normal gastric tissues and tumor-adjacent tissues of 22 gastric cancer patients (between January and July, 2007) were obtained from the Xiehe Hospital of Tongji Medical College, after approval of the Institutional Review Board. Tumor tissues were divided into two groups. One group was fixed in 10% formalin, embedded in paraffin and stained with hematoxylin and eosin and immunohistochemistry. The other group was snap-frozen in liquid nitrogen and stored at -80˚C for RNA extraction. The patients comprised 13 men and eight women aged 36-79 (mean: 56.9 years). Prior to surgery, none of the patients received any anti-cancer treatment. The tumor size, histological differentiation, T stage and N stage were evaluated according to the clinicopathological classification of the WHO (2003).
RT-PCR amplification.
For RT-PCR analysis, gastric cancer cells and frozen tissues of gastric adenocarcinoma were disrupted in TRIzol reagent (Invitrogen, San Diego, CA, USA) and total RNA was isolated according to the manufacturer's instructions. Total RNA was reversely transcribed into cDNA by RT-PCR kit (Takara, Dalian, China). Following reverse transcription, PCR reaction was carried out with 35 cycles using the following conditions: 94˚C for 40 sec, 60˚C for 1 min and 72˚C for 40 sec. ER-·36 primers and GAPDH Primers were designed by Primer 5.0 (Primer Biosoft International, Palo Alto, CA, USA) and were used simultaneously in the same reaction. The following primers were used: ER-·36 forward primer 5'-CAAGTGGTTTCCTCGTGTCTAAAG-3'; ER-·36 reverse primer 5'-TGTTGAGTGTTGGTTGCC AGG-3'; GAPDH forward primer 5'-ACCACAGTCCATG CCATCAC-3'; GAPDH reverse primer 5'-TCCACCACCC TGTTGCTGTA-3'. The PCR products (219 bp for ER-·36 and 452 bp for GAPDH) were separated on 1.5% agarose gel and stained with GoldView (SBS Genetech Co., Beijing, China). The densities of DNA bands were assessed with the analysis software (Biostep Photoimpact, Beijing, China) and the relative values were determined.
Western blot assay. Cells were lysed with the RIPA buffer (Beyotime, Shanghai, China). Proteins concentration was determined with an Enhanced BCA Protein assay kit (Beyotime). Cell lysates were mixed with gel-loading buffer, separated by 12% SDS-PAGE gels and transferred to a PVDF membrane (Millipore, Billerica, MA, USA). The membrane was probed with the indicated antibodies and visualized with the appropriate secondary antibodies (Beyotime) and enhanced chemiluminescence (ECL) reagents (Beyotime). The densities of protein bands were determined with the Totallab analysis software (Nonlinear Dynamics Technical, NC, USA). The rabbit polyclonal ER-·36 antibody was development as described before (9) . The anti-ß-actin (C4) antibody was purchased from Santa Cruz Biotechnology (CA, USA).
Immunofluorescence and immunohistochemistry assays. Gastric cancer cells cultured on cover glass were fixed with acetone for 10 min. After washing with PBS, cells were permeabilized with 0.5% (V/V) Triton X-100 for 10 min, washed with PBS and blocked with 3% serum in PBS at room temperature for 1 h. The cover glasses were incubated with the rabbit polyclonal ER-·36 antibody at room temperature for 1 h and washed 3 times with PBS containing 0.5% Triton X-100 (PBST), then incubated with a Cy3-labeled secondary antibody (Beyotime). The specificity of staining was verified by omitting the primary antibody. Finally, the cover glasses were washed 3 times with PBST, one time with PBS, then mounted with anti-fade medium (Molecular Probes, Eugene, OR, USA) and examined under a Olympus microscope at x400 magnification. Hoechst 33258 was used for nuclear staining.
Immunohistochemical staining was performed on 4-μm thick tumor sections via a 'two-step' assay. Briefly, tissue slides were deparaffinized with xylene and rehydrated through a gradual alcohol series. The endogenous peroxidase activity was blocked by incubation in a 3% hydrogen peroxide/ methanol buffer for 10 min. Antigen retrieval was carried out by immersing the slides in EDTA buffer (pH 8.0) and boiling in a water-bath at 95˚C for 25 min. The slides were rinsed in phosphate-buffered saline (PBS) and incubated with normal goat serum to block non-specific staining. The slides were then incubated with the polyclonal anti-ER-·36 antibody at a dilution of 1:50 overnight at 4˚C in a humidified chamber. The slides were incubated with the second antibody (horseradish peroxidase-conjugated goat anti-rabbit immunoglobin; 1:100, Dako, CA, USA) for 45 min. Diaminobenzidine was used as a chromagen and slides were counterstained with hematoxylin. Scoring for ER-·36 staining was graded as follows: no staining or staining observed in (10% of tumor cells was given a score 0; faint/barely perceptible staining detected in ≥10% of tumor cells was scored as 1+; a moderate or strong staining observed in ≥10% of tumor cells was scored as 2+ or 3+, respectively. A score of 0 and 1+ was considered negative whereas 2+ and 3+ were considered positive. Immunostained slides were evaluated by two pathologists independently in a blinded manner. In most cases, the evaluations of the two pathologists were identical; any discrepancies were resolved by re-examination and consensus.
Statistical analysis. The correlation between ER-·36 expression and clinic pathologic characteristics was determined using Pearson's ¯2 test. P<0.05 was considered statistical significance. The statistical analyses were performed using SPSS 12.0 software.
Results

ER-·36 is expressed in established gastric cancer cell lines.
To determine whether the estrogen receptor variant, ER-·36 is expressed in gastric cancer, we examined ER-·36 expression in four gastric cancer cell lines including SGC-7901, AGS, BGC-923 and MKN-45 with Western blot analysis. Fig. 1 shows that higher levels of ER-·36 protein were detected in all four gastric cancer cell lines compared to ER-positive breast cancer MCF-7 cells. In addition, RT-PCR analysis confirmed ER-·36 mRNA was also highly expressed in all cell lines (Fig. 2) . These results demonstrated that the novel variant of ER-·36 is highly expressed in established gastric cancer cells.
Previously, we demonstrated that ER-·36 is mainly expressed on the plasma membrane and in the cytoplasm of breast cancer cells (19) . We decided to determine the localization of ER-·36 in gastric cancer cells. Indirect immunofluorescence assay with a specific anti-ER-·36 antibody revealed that ER-·36 is highly expressed outside of the cell nuclei; mainly on the plasma membrane and in the cytoplasm of the gastric cancer cells (Fig. 3) .
ER-·36 expression is detected in human gastric adenocarcinoma tissues.
To determine the expression patterns of ER-·36 in gastric adenocarcinoma tissues, the immunohistochemistry (IHC) assay was performed in specimens from 22 gastric cancer patients. The results showed that ER-·36 is expressed in 18 of 22 (81.8%) specimens of primary gastric adenocarcinoma examined consistent with the results with established gastric cancer cell lines. We observed that ER-·36 exhibited cytoplasmic and membranous patterns in tumor specimens ( Fig. 4) .
We also performed RT-PCR analysis to assess expression levels of ER-·36 transcripts. ER-·36 transcripts were detected in tumor tissues (T), adjacent non-malignant tissues (A) and corresponding normal tissues (N) of all 22 gastric cancer patients (data not shown). Higher-levels of ER-·36 mRNA expression were detected in 17 of 22 (77.27%) tumor specimens compared with the paired normal tissues (p<0.01). Fig. 5 shows RT-PCR results from four representative cases. In comparison with corresponding normal tissues, levels of ER-·36 mRNA expression were increased in tumor tissues of cases 1, 3 and 4 human gastric cancers (Fig. 5 ). 
ER-·36 expression is correlated with lymph node metastasis.
We also assessed whether ER-·36 expression correlated with the clinicopathological properties of gastric adenocarcinoma. Table I shows that ER-·36 expression was not associated with gender, age, tumor size, histological differentiation and tumor stage. However, ER-·36 expression was significantly associated with lymph node metastasis (P=0.0372).
Discussion
Previous studies have reported conflicting expression results for the classical ER-· (ER-·66) in gastric cancer (20) (21) (22) (23) (24) (25) . Using the immunohistochemical method, gastric tumor tissues were often considered as ER-negative or low-expression tissues (2-28% of the tumors) (20, 21) . It was reported that in gastric cancer, ER-·66 expression showed no difference between cancerous and normal tissues and no correlation with tumor grade (22) . However, in other studies, it was found that ER-·66 expression in gastric cancer correlated with a worse prognosis (23) and more widespread lymph node metastasis (24, 25) . Thus, the expression and possible function of ER-·66 in development of human gastric cancer is controversial.
In this study, we found that ER-·36 is highly expressed in established gastric cancer cell lines including SGC-7901, AGS, BGC-923, and MKN-45. Using indirect immunofluorescence staining, we demonstrated that ER-·36 was mainly expressed on the plasma membrane and in the cytoplasm of gastric cancer cells. Both ER-·36 mRNA and protein were also detected in most specimens from human gastric cancer patients; exhibiting higher levels of expression compared to their matched normal tissues. Our results thus for the first time indicated that the ER-· variant ER-·36 is highly expressed in human gastric adenocarcinoma tissues and suggested that the non-genomic estrogen signaling mediated by ER-·36 may be involved in gastric carcinogenesis.
We also found that ER-·36 protein was mainly expressed on the plasma membrane and in the cytoplasm of gastric cancer specimens. It is worth noting that a weak cytoplasmic pattern of ER-·66 expression was frequently observed in ER-·36-expressing breast cancer tissues while mainly in the cell nuclei in ER-·36-negative breast cancer cells (19) , suggesting that ER-·36 expression may influence ER-·66 cellular localization. Previously, it was reported that ER-·66 expression was observed predominantly in the cytoplasm of gastric cancer cells (18) . Thus, it is possible that these cells might also express ER-·36.
We further found that high levels of ER-·36 expression significantly correlated with lymph node metastasis in gastric cancer. Lymph node metastasis is one of the most important prognostic factors in gastric cancer. Thus, enhanced ER-·36 expression in gastric adenocarcinoma may be involved in increased metastasis, suggesting that ER-·36 expression can be used as a predictive marker for metastasis. -------------------------------------------------
